Isabella Nava

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9147116/publications.pdf

Version: 2024-02-01

43 papers	1,239 citations	430843 18 h-index	361001 35 g-index
43 all docs	43 docs citations	43 times ranked	1718 citing authors

#	Article	IF	Citations
1	COVID-19, inflammatory response, iron homeostasis and toxicity: a prospective cohort study in the Emergency Department of Piacenza (Italy).. Acta Biomedica, 2022, 93, e2022057.	0.3	1
2	Epidemiological shift of glucose-6-phosphate dehydrogenase mutations in northern Italy in the last 15Âyears. Annals of Hematology, 2021, 100, 2683-2688.	1.8	2
3	ACTIVIN RECEPTOR LIGAND FOR THR TREATMENT OF BETA-THALASSEMIA: a SERENDIPITOUS DISCOVERY. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020075.	1.3	4
4	Microcytosis in Erythropoietic Protoporphyria. Blood, 2020, 136, 44-44.	1.4	0
5	Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation. British Journal of Haematology, 2019, 185, 523-531.	2.5	6
6	Inflammatory involvement into phototoxic reaction in erythropoietic protoporphyria (EPP) patients. Immunologic Research, 2019, 67, 382-389.	2.9	11
7	Evaluation of in Vitro Macrophage Characterization in Gaucher Type 1 (GD1) Patients. Blood, 2019, 134, 3592-3592.	1.4	0
8	Nonâ€transferrinâ€bound iron and oxidative stress during allogeneic hemopoietic stem cell transplantation in patients with or without iron overload. American Journal of Hematology, 2018, 93, E250-E252.	4.1	15
9	Circulating cellâ€free DNA and ineffective erythropoiesis in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2018, 93, E365-E368.	4.1	2
10	Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-12.	1.9	25
11	Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications. Leukemia Research, 2015, 39, 88-91.	0.8	18
12	The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. American Journal of Hematology, 2015, 90, 306-309.	4.1	32
13	Does TMPRSS6 RS855791 Polymorphism Contribute to Iron Deficiency in Treated Celiac Disease?. American Journal of Gastroenterology, 2015, 110, 200-202.	0.4	23
14	Role of Non-Transferrin-Bound Iron in the pathogenesis of cardiotoxicity in patients with ST-elevation myocardial infarction assessed by Cardiac Magnetic Resonance Imaging. International Journal of Cardiology, 2015, 199, 326-332.	1.7	16
15	Growth Differentiation Factor 15 expression and regulation during erythroid differentiation in non-transfusion dependent thalassemia. Blood Cells, Molecules, and Diseases, 2015, 54, 26-28.	1.4	10
16	Combination of deferasirox and deferoxamine in clinical practice: An alternative scheme of chelation in thalassemia major patients. Blood Cells, Molecules, and Diseases, 2014, 53, 164-167.	1.4	39
17	An Intriguing Case of Anaemia and Splenomegaly. European Journal of Case Reports in Internal Medicine, 2014, 1, .	0.4	1
18	Very high frequency of <scp>TMPRSS6</scp> gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?. British Journal of Haematology, 2013, 161, 147-150.	2.5	3

#	Article	IF	Citations
19	Analysis Of TMPRSS6 Polymorphisms In Patients With Iron Deficiency Anemia Partially Responsive To Oral Iron Treatment. Blood, 2013, 122, 3438-3438.	1.4	1
20	Fetal hemoglobin levels and morbidity in untransfused patients with Î²-thalassemia intermedia. Blood, 2012, 119, 364-367.	1.4	85
21	Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial. Movement Disorders, 2012, 27, 446-449.	3.9	57
22	Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with Î² thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2011, 47, 232-234.	1.4	55
23	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. PLoS ONE, 2011, 6, e23109.	2.5	95
24	Nontransferrin-bound iron in transfused patients with sickle cell disease. International Journal of Laboratory Hematology, 2011, 33, 133-137.	1.3	11
25	Hepcidin mutation in a Î²-thalassemia major patient with persistent severe iron overload despite chelation therapy. Internal and Emergency Medicine, 2010, 5, 83-85.	2.0	3
26	Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. British Journal of Haematology, 2010, 151, 281-284.	2.5	33
27	High nontransferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology, 2009, 84, 29-33.	4.1	128
28	Mutation analysis of hepcidin and ferroportin genes in Italian prospective blood donors with iron overload. American Journal of Hematology, 2009, 84, 592-593.	4.1	7
29	Levels of nonâ€transferrinâ€bound iron as an index of iron overload in patients with thalassaemia intermedia. British Journal of Haematology, 2009, 146, 569-572.	2.5	66
30	Iron Burden and Liver Fibrosis Decrease During a Long-Term Phlebotomy Program and Iron Chelating Treatment After Bone Marrow Transplantation. Hemoglobin, 2006, 30, 131-137.	0.8	12
31	Changes in erythropoiesis, iron metabolism and oxidative stress after half-marathon. Internal and Emergency Medicine, 2006, 1, 30-34.	2.0	18
32	Identification of a New Mutation in the 5â€²-UTR of Hepcidin Gene in beta-Thalassemia Major (TM) Patients.. Blood, 2006, 108, 3811-3811.	1.4	0
33	Erythrocyte ferritin concentration: analytical performance of the immunoenzymatic IMx-Ferritin (Abbott) assay. Clinical Chemistry and Laboratory Medicine, 2005, 43, 449-53.	2.3	9
34	Design of a trial comparing sirolimus plus mycophenolate mofetil versus sirolimus plus cyclosporine. Transplantation Proceedings, 2003, 35, S62-S63.	0.6	1
35	Red blood cell antioxidant and iron status in alcoholic and nonalcoholic cirrhosis. European Journal of Clinical Investigation, 2002, 32, 21-27.	3.4	16
36	Oxidative status and malondialdehyde in Î²-thalassaemia patients. European Journal of Clinical Investigation, 2002, 32, 55-60.	3.4	115

#	Article	IF	Citations
37	Membraneâ€bound iron contributes to oxidative damage of Î²â€thalassaemia intermedia erythrocytes. British Journal of Haematology, 2001, 112, 48-50.	2.5	68
38	Non-Transferrin-Bound Iron in Alcohol Abusers. Alcoholism: Clinical and Experimental Research, 2001, 25, 1494-1499.	2.4	16
39	Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in Î²-thalassemia intermedia. Transfusion Science, 2000, 23, 245-246.	0.6	22
40	Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. The Hematology Journal, 2000, 1, 153-158.	1.4	62
41	Metabolic indicators of oxidative stress correlate with haemichrome attachment to membrane, band 3 aggregation and erythrophagocytosis in Î²â€thalassaemia intermedia. British Journal of Haematology, 1999, 104, 504-512.	2.5	76
42	Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. Hepatology, 1999, 29, 658-663.	7.3	74
43	Erythrocyte membrane alterations in thalassemia intermedia. Clinical Hemorheology and Microcirculation, 1996, 16, 789-797.	1.7	1